Compare Nvidia Corp (NVDA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs TG Therapeutics Inc — how do they compare? Nvidia Corp trades at $222.44 (market cap $5.27T), while TG Therapeutics Inc trades at $49.59 (market cap $7.64B). The key difference: Nvidia Corp is far larger — about 689.8× TG Therapeutics Inc's market cap, and Nvidia Corp pays a 0.46% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NVDA | TGTX | |
|---|---|---|
Market Cap | $5.27T | $7.64B |
Sector | Technology | Health |
52-Week High | $235.75 | $59.06 |
52-Week Low | $165.17 | $26.94 |
Enterprise Value | $5.20T | $7.84B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $223.75, up 2.85% today, near its R3 resistance of $224. The stock shows strong fundamentals with revenue surging to $130.50B in 2025 and net income at $72.88B, driven by AI chip demand. Recent earnings beats and a bullish analyst consensus of 75% buy ratings support momentum, though RSI levels hint at overbought conditions.
Outlook remains positive with a $325.86 price target, but risks include peak AI spending concerns and competition. Growth is sustainable if execution continues, yet volatility from macroeconomic factors warrants caution for new positions.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
